LT3322734T - Daugiavalenčiai ir daugiaspecifiniai dr5 rišantys jungiamieji baltymai - Google Patents

Daugiavalenčiai ir daugiaspecifiniai dr5 rišantys jungiamieji baltymai

Info

Publication number: LT3322734T
Authority: LT; Lithuania
Prior art keywords: multispecific; multivalent; fusion proteins; binding fusion; binding
Prior art date: 2015-07-16

Application number

LTEP16825315.1T

Other languages

English (en)

Inventor

John C. Timmer

Kyle S. JONES

Amir S. RAZAI

Abrahim HUSSAIN

Katelyn M. WILLIS

Quinn Deveraux

Brendan P. Eckelman

Original Assignee

Inhibrx, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-16

Filing date

2016-07-18

Publication date

2021-02-10

2016-07-18 Application filed by Inhibrx, Inc. filed Critical Inhibrx, Inc.

2021-02-10 Publication of LT3322734T publication Critical patent/LT3322734T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LTEP16825315.1T 2015-07-16 2016-07-18 Daugiavalenčiai ir daugiaspecifiniai dr5 rišantys jungiamieji baltymai LT3322734T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562193309P	2015-07-16	2015-07-16
PCT/US2016/042862 WO2017011837A2 (en)	2015-07-16	2016-07-18	Multivalent and multispecific dr5-binding fusion proteins

Publications (1)

Publication Number	Publication Date
LT3322734T true LT3322734T (lt)	2021-02-10

Family

ID=57757772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP16825315.1T LT3322734T (lt)	2015-07-16	2016-07-18	Daugiavalenčiai ir daugiaspecifiniai dr5 rišantys jungiamieji baltymai

Country Status (25)

Country	Link
US (4)	US10308720B2 (lt)
EP (2)	EP3322734B1 (lt)
JP (4)	JP6807606B2 (lt)
KR (2)	KR102760380B1 (lt)
CN (2)	CN114106178A (lt)
AU (3)	AU2016291701B2 (lt)
CA (2)	CA3288875A1 (lt)
CY (1)	CY1123615T1 (lt)
DK (1)	DK3322734T3 (lt)
ES (1)	ES2833773T3 (lt)
HR (1)	HRP20201785T1 (lt)
HU (1)	HUE051896T2 (lt)
IL (3)	IL307994A (lt)
LT (1)	LT3322734T (lt)
MX (2)	MX2018000523A (lt)
NZ (1)	NZ777930A (lt)
PL (1)	PL3322734T3 (lt)
PT (1)	PT3322734T (lt)
RS (1)	RS61062B1 (lt)
RU (2)	RU2748620C2 (lt)
SG (1)	SG10201912410TA (lt)
SI (1)	SI3322734T1 (lt)
SM (1)	SMT202100066T1 (lt)
WO (1)	WO2017011837A2 (lt)
ZA (1)	ZA201800238B (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018191438A1 (en)	2017-04-11	2018-10-18	Inhibrx, Inc.	Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN111819198A (zh) *	2017-12-28	2020-10-23	尤利乌斯·马克西米利安维尔茨堡大学	具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
CN110305210B (zh) *	2018-03-27	2023-02-28	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
IL277863B2 (en)	2018-04-11	2026-02-01	Inhibrx Inc	Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
WO2020047705A1 (zh) *	2018-09-03	2020-03-12	安菲尼生命科技有限公司	Dr5单域抗体及其用途
GB201903767D0 (en) *	2019-03-19	2019-05-01	Quadrucept Bio Ltd	Multimers, tetramers & octamers
BR112022006364A2 (pt) *	2019-10-01	2022-06-28	Epsilogen Ltd	Anticorpo híbrido
CN115698088A (zh) *	2020-06-30	2023-02-03	和铂医药(上海)有限责任公司	免疫细胞衔接器多特异性结合蛋白及其制备和应用
WO2022002033A1 (zh) *	2020-06-30	2022-01-06	和铂医药(上海)有限责任公司	具有H2L2与HCAb结构的结合蛋白
CN115667316A (zh) *	2020-06-30	2023-01-31	和铂医药(上海)有限责任公司	Fab-HCAb结构的结合蛋白
IL305265A (en) *	2021-02-19	2023-10-01	Inhibrx Inc	Preparations of DR5-binding polypeptides
CN119365489A (zh) *	2022-04-08	2025-01-24	印希比生物科学有限公司	Dr5激动剂与plk1抑制剂或cdk抑制剂组合疗法
CA3254393A1 (en) *	2022-05-23	2023-11-30	Inhibrx Biosciences, Inc.	DR5 AGONIST AND IAP ANTAGONIST POLYTHERAPY
JP2025534309A (ja)	2022-09-28	2025-10-15	ヴァリンクセラピューティクスリミテッド	多価タンパク質およびスクリーニング法
KR20260032566A (ko) *	2023-06-29	2026-03-09	오디세이 테라퓨틱스, 인코포레이티드	항-trailr2 항원-결합 단백질 및 그의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69131017T2 (de)	1990-12-20	1999-07-15	Ixsys, Inc., San Diego, Calif.	Optimierung von bindenden proteinen
US20020147140A1 (en) *	2000-01-31	2002-10-10	Rosen Craig A.	Nucleic acids, proteins, and antibodies
KR20070010046A (ko) *	2004-04-06	2007-01-19	제넨테크, 인크.	Ｄｒ5 항체 및 그의 용도
EA200701211A1 (ru)	2004-12-31	2007-12-28	Дженентек, Инк.	Полипептиды, которые связываются с br3, и их применение
MX2007010349A (es)	2005-02-24	2008-04-09	Cemines Inc	Composiciones y metodos para clasificar muestras biologicas.
CA2619725C (en)	2005-08-18	2016-06-07	Ramot At Tel Aviv University Ltd.	Single chain antibodies against beta-amyloid peptide
TW200804425A (en)	2005-12-06	2008-01-16	Domantis Ltd	Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
DK1987178T3 (en)	2006-02-20	2015-04-20	Phylogica Ltd	Process for the construction and screening of peptide structure libraries
JP2008133206A (ja)	2006-11-28	2008-06-12	Yokohama City Univ	緑膿菌に対して感染防御能を誘導できる医薬組成物
SG186017A1 (en)	2007-11-30	2012-12-28	Kalobios Pharmaceuticals Inc	Antibodies to the pcrv antigen of pseudomonas aeruginosa
HUE042053T2 (hu)	2008-06-05	2019-06-28	Ablynx Nv	Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
EP2328929A2 (en) *	2008-09-10	2011-06-08	Bac Ip B.V.	Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
US9096659B2 (en)	2009-03-18	2015-08-04	Wake Forest University Health Sciences	Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa
US20100281003A1 (en)	2009-04-02	2010-11-04	New York University	System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) *	2009-11-13	2012-01-04	厦门大学	抗人死亡受体5的单链抗体基因
HRP20251657T1 (hr)	2009-12-14	2026-02-13	Ablynx N.V.	Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
US9120855B2 (en) *	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
WO2011134060A1 (en)	2010-04-27	2011-11-03	National Research Council Of Canada	Anti-icam-1 single domain antibody and uses thereof
NZ607473A (en)	2010-09-27	2014-11-28	Morphosys Ag	Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
US9771416B2 (en)	2010-10-25	2017-09-26	National Research Council Of Canada	Clostridium difficile-specific antibodies and uses thereof
KR20130133212A (ko)	2010-12-23	2013-12-06	인터셀 오스트리아 아게	입원 및 다른 환자에서 OprF/I 물질 및 이의 용도
PE20141522A1 (es)	2011-08-17	2014-11-17	Glaxo Group Ltd	Proteinas y peptidos modificados
SMT202000091T1 (it) *	2011-10-13	2020-05-08	Bristol Myers Squibb Co	Polipeptidi anticorpali che antagonizzano cd40l
ES2749349T3 (es)	2011-11-07	2020-03-19	Medimmune Llc	Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
JP6170940B2 (ja)	2011-12-20	2017-07-26	アダエラータ、リミテッドパートナーシップＡｄａｅｒａｔａ，ＬｉｍｉｔｅｄＰａｒｔｎｅｒｓｈｉｐ	Ｐｃｓｋ９の阻害剤としての単一ドメイン抗体
MX2014010495A (es)	2012-03-02	2014-11-14	Ablynx Nv	Polipeptidos que enlazan a pcrv.
WO2013167883A1 (en)	2012-05-07	2013-11-14	The University Court Of The University Of Aberdeen	Single domain binding molecule
EP2684896A1 (en) *	2012-07-09	2014-01-15	International-Drug-Development-Biotech	Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US20140161796A1 (en)	2012-09-13	2014-06-12	Andreas Loew	Single chain proteins with c-terminal modifications
JP2015535005A (ja)	2012-11-06	2015-12-07	メディミューン，エルエルシー	抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
CN102924600B (zh) *	2012-11-14	2013-10-30	河南大学	死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
US9862777B2 (en)	2013-05-28	2018-01-09	Vib Vzw	Single domain antibodies against SOD1 and their use in medicine
CA2936053A1 (en) *	2014-01-10	2015-07-16	Teikyo Heisei University	Recombinant obligate anaerobic gram-positive bacteria

2016
- 2016-07-18 CN CN202111039963.9A patent/CN114106178A/zh active Pending
- 2016-07-18 JP JP2018501345A patent/JP6807606B2/ja active Active
- 2016-07-18 IL IL307994A patent/IL307994A/en unknown
- 2016-07-18 RS RS20201315A patent/RS61062B1/sr unknown
- 2016-07-18 SG SG10201912410TA patent/SG10201912410TA/en unknown
- 2016-07-18 NZ NZ777930A patent/NZ777930A/en unknown
- 2016-07-18 PL PL16825315T patent/PL3322734T3/pl unknown
- 2016-07-18 DK DK16825315.1T patent/DK3322734T3/da active
- 2016-07-18 AU AU2016291701A patent/AU2016291701B2/en active Active
- 2016-07-18 KR KR1020187000975A patent/KR102760380B1/ko active Active
- 2016-07-18 EP EP16825315.1A patent/EP3322734B1/en active Active
- 2016-07-18 CA CA3288875A patent/CA3288875A1/en active Pending
- 2016-07-18 LT LTEP16825315.1T patent/LT3322734T/lt unknown
- 2016-07-18 HU HUE16825315A patent/HUE051896T2/hu unknown
- 2016-07-18 MX MX2018000523A patent/MX2018000523A/es unknown
- 2016-07-18 IL IL292037A patent/IL292037A/en unknown
- 2016-07-18 RU RU2018102803A patent/RU2748620C2/ru active
- 2016-07-18 HR HRP20201785TT patent/HRP20201785T1/hr unknown
- 2016-07-18 CA CA2991634A patent/CA2991634C/en active Active
- 2016-07-18 EP EP20189995.2A patent/EP3798232A1/en active Pending
- 2016-07-18 US US15/213,296 patent/US10308720B2/en active Active
- 2016-07-18 ES ES16825315T patent/ES2833773T3/es active Active
- 2016-07-18 SM SM20210066T patent/SMT202100066T1/it unknown
- 2016-07-18 SI SI201631005T patent/SI3322734T1/sl unknown
- 2016-07-18 KR KR1020257002277A patent/KR20250017305A/ko active Pending
- 2016-07-18 PT PT168253151T patent/PT3322734T/pt unknown
- 2016-07-18 WO PCT/US2016/042862 patent/WO2017011837A2/en not_active Ceased
- 2016-07-18 RU RU2021111382A patent/RU2021111382A/ru unknown
- 2016-07-18 CN CN201680041274.2A patent/CN107922491B/zh active Active
2018
- 2018-01-07 IL IL256772A patent/IL256772B/en unknown
- 2018-01-12 MX MX2023002379A patent/MX2023002379A/es unknown
- 2018-01-12 ZA ZA2018/00238A patent/ZA201800238B/en unknown
2019
- 2019-04-18 US US16/387,754 patent/US11117973B2/en active Active
2020
- 2020-11-16 CY CY20201101085T patent/CY1123615T1/el unknown
- 2020-11-26 JP JP2020196358A patent/JP7244938B2/ja active Active
2021
- 2021-08-05 US US17/394,900 patent/US11976126B2/en active Active
2022
- 2022-11-30 JP JP2022191038A patent/JP2023022214A/ja active Pending
- 2022-12-21 AU AU2022291498A patent/AU2022291498A1/en not_active Abandoned
2024
- 2024-04-04 US US18/626,699 patent/US20240376220A1/en active Pending
2025
- 2025-03-03 JP JP2025032594A patent/JP2025084923A/ja active Pending
2026
- 2026-01-16 AU AU2026200317A patent/AU2026200317A1/en active Pending

Also Published As

Publication number	Publication date
WO2017011837A2 (en)	2017-01-19
WO2017011837A3 (en)	2017-03-02
CA2991634C (en)	2026-03-17
ZA201800238B (en)	2021-07-28
RU2018102803A (ru)	2019-08-19
MX2023002379A (es)	2023-03-21
NZ777930A (en)	2025-05-02
JP2018522888A (ja)	2018-08-16
JP2025084923A (ja)	2025-06-03
IL292037A (en)	2022-06-01
CA2991634A1 (en)	2017-01-19
KR20250017305A (ko)	2025-02-04
US20220064318A1 (en)	2022-03-03
US20240376220A1 (en)	2024-11-14
CN107922491B (zh)	2021-09-28
KR20180030518A (ko)	2018-03-23
HK1254433A1 (en)	2019-07-19
EP3798232A1 (en)	2021-03-31
CN114106178A (zh)	2022-03-01
KR102760380B1 (ko)	2025-01-31
CY1123615T1 (el)	2022-03-24
US20170015753A1 (en)	2017-01-19
HRP20201785T1 (hr)	2021-01-22
RU2748620C2 (ru)	2021-05-28
US11117973B2 (en)	2021-09-14
RS61062B1 (sr)	2020-12-31
SI3322734T1 (sl)	2021-02-26
HUE051896T2 (hu)	2021-03-29
US10308720B2 (en)	2019-06-04
PT3322734T (pt)	2020-11-30
AU2026200317A1 (en)	2026-02-05
RU2018102803A3 (lt)	2019-12-27
JP6807606B2 (ja)	2021-01-06
IL307994A (en)	2023-12-01
CN107922491A (zh)	2018-04-17
CA3288875A1 (en)	2026-03-02
EP3322734A2 (en)	2018-05-23
RU2021111382A (ru)	2021-05-21
EP3322734A4 (en)	2019-04-17
IL256772A (en)	2018-03-29
DK3322734T3 (da)	2020-10-26
NZ738850A (en)	2024-11-29
AU2016291701A1 (en)	2018-01-25
BR112018000584A2 (pt)	2018-09-11
AU2016291701B2 (en)	2022-09-29
JP2023022214A (ja)	2023-02-14
US20190309083A1 (en)	2019-10-10
US11976126B2 (en)	2024-05-07
IL256772B (en)	2022-05-01
EP3322734B1 (en)	2020-09-09
PL3322734T3 (pl)	2021-05-04
SG10201912410TA (en)	2020-02-27
ES2833773T3 (es)	2021-06-15
JP2021046414A (ja)	2021-03-25
SMT202100066T1 (it)	2021-03-15
JP7244938B2 (ja)	2023-03-23
MX2018000523A (es)	2018-04-13
AU2022291498A1 (en)	2023-02-02

Publication	Publication Date	Title
SG10201913807QA (en)	2020-03-30	Multivalent and multispecific gitr-binding fusion proteins
SG10201912405TA (en)	2020-02-27	Multivalent and multispecific 41bb-binding fusion proteins
ZA201800238B (en)	2021-07-28	Multivalent and multispecific dr5-binding fusion proteins
IL254965B (en)	2021-03-25	fusion proteins
GB201509413D0 (en)	2015-07-15	Fusion protein
GB201509062D0 (en)	2015-07-08	OX40L fusion proteins and uses thereof
EP3262022A4 (en)	2018-08-15	Phenylethynylnaphthalene dyes and methods for their use
IL246355B (en)	2020-06-30	p97–ids fused proteins
GB201504691D0 (en)	2015-05-06	Fusion protein
GB201515745D0 (en)	2015-10-21	Proteins
GB201511787D0 (en)	2015-08-19	Proteins
ZA201606327B (en)	2019-01-30	Uti fusion proteins
SG11201606501PA (en)	2016-09-29	Nanobody-fluorescent protein fusion
ZA201801394B (en)	2020-07-29	Fusion protein
GB201513033D0 (en)	2015-09-09	Proteins
EP3237452A4 (en)	2018-12-05	Fusion proteins and methods thereof
GB201602850D0 (en)	2016-04-06	Fusion proteins
IL244857A0 (en)	2016-07-31	A fusion protein of acetylcholinesterase and the fc region
HK1255651A1 (en)	2019-08-23	Multivalent and multispecific gitr-binding fusion proteins
HK1261500A1 (en)	2020-01-03	Multivalent and multispecific 41bb-binding fusion proteins
HK1261708A1 (en)	2020-01-03	Multivalent and multispecific ox40-binding fusion proteins
GB201515744D0 (en)	2015-10-21	Proteins
GB201503778D0 (en)	2015-04-22	Proteins